Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on LinkedIn about a paper published in NEJM:
“Longer Duration of ICI Therapy Linked to Higher Complete Response Rates in MMRd Cancers!
A systematic review published in NEJM Group found that longer neoadjuvant treatment with immune checkpoint inhibitors (ICIs) is associated with higher complete response rates in patients with mismatch repair-deficient (MMRd) cancers.
- Anti-PD1 therapy alone for MMRd colorectal cancer (1–7 months): Complete response ranged from 0% to 100%
- Anti-PD1 + anti-CTLA4 (shorter duration to reduce toxicity): 68% CR (4 weeks) – 80% CR (6 weeks)
- Longer treatment is expected to improve tumour ablation rates.”
“The Duration of Immunotherapy for Mismatch Repair-Deficient Cancers”
M0re posts featuring Elvina Almuradova.